*Review* **Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review**

**Jun-O Jin 1,2,\* ,† , Dhananjay Yadav 3,† , Kajal Madhwani 4,† , Nidhi Puranik <sup>5</sup> , Vishal Chavda 6,7,\* and Minseok Song 3,\***


**Abstract:** Marine natural products are a discerning arena to search for the future generation of medications to treat a spectrum of ailments. Meanwhile, cancer is becoming more ubiquitous over the world, and the likelihood of dying from it is rising. Surgery, radiation, and chemotherapy are the mainstays of cancer treatment worldwide, but their extensive side effects limit their curative effect. The quest for low-toxicity marine drugs to prevent and treat cancer is one of the current research priorities of researchers. Fucoidan, an algal sulfated polysaccharide, is a potent therapeutic lead candidate against cancer, signifying that far more research is needed. Fucoidan is a versatile, nontoxic marine-origin heteropolysaccharide that has received much attention due to its beneficial biological properties and safety. Fucoidan has been demonstrated to exhibit a variety of conventional bioactivities, such as antiviral, antioxidant, and immune-modulatory characteristics, and anticancer activity against a wide range of malignancies has also recently been discovered. Fucoidan inhibits tumorigenesis by prompting cell cycle arrest and apoptosis, blocking metastasis and angiogenesis, and modulating physiological signaling molecules. This review compiles the molecular and cellular aspects, immunomodulatory and anticancer actions of fucoidan as a natural marine anticancer agent. Specific fucoidan and membranaceous polysaccharides from *Ecklonia cava*, *Laminaria japonica*, *Fucus vesiculosus*, *Astragalus*, *Ascophyllum nodosum*, *Codium fragile* serving as potential anticancer marine drugs are discussed in this review.

**Keywords:** seaweeds; marine algae; marine drugs; fucoidan; sulfated polysaccharide; cancer; adjuvant; prebiotics
